Atezolizumab combination improves OS for non-small cell lung cancer

The addition of first-line atezolizumab to bevacizumab plus chemotherapy improved survival among patients with non-small cell lung cancer, according to interim results from the phase 3 IMpower150 study.

Researchers observed a survival benefit across key subgroups, including those with PD-L1 expression.

Atezolizumab (Tecentriq, Genentech) is a monoclonal antibody designed to bind with PD-L1. The randomized, multicenter, open-label IMpower150 study assessed the efficacy and safety of atezolizumab in combination with chemotherapy with or without bevacizumab (Avastin, Genentech) among 1,202 patients with stage IV nonsquamous NSCLC.

Researchers randomly assigned patients 1:1:1 to atezolizumab plus carboplatin and paclitaxel, atezolizumab and bevacizumab plus carboplatin and paclitaxel, or bevacizumab plus carboplatin and paclitaxel.

Researchers excluded patients with ALK and EGFR mutations from the intention-to-treat analysis.

The study met its co-primary endpoint of OS with atezolizumab and bevacizumab plus chemotherapy, which appeared associated with increased survival compared with bevacizumab plus chemotherapy.

Atezolizumab plus chemotherapy did not appear to have a significant OS benefit compared with bevacizumab plus chemotherapy.

As HemOnc Today previously reported, atezolizumab and bevacizumab plus chemotherapy extended PFS by 38% among patients with NSCLC (HR = 0.62; 95% CI, 0.52-0.74) compared with bevacizumab plus chemotherapy.

The safety profile of the combination appeared consistent with the known safety profile of the individual agents.

“We are pleased that the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech, said in a company-issued press release. “These results add to the growing body of evidence supporting the role of combining Tecentriq with Avastin. We will submit these additional data to global health authorities and hope to bring this potential treatment option to patients as soon as possible.”

The addition of first-line atezolizumab to bevacizumab plus chemotherapy improved survival among patients with non-small cell lung cancer, according to interim results from the phase 3 IMpower150 study.

Researchers observed a survival benefit across key subgroups, including those with PD-L1 expression.

Atezolizumab (Tecentriq, Genentech) is a monoclonal antibody designed to bind with PD-L1. The randomized, multicenter, open-label IMpower150 study assessed the efficacy and safety of atezolizumab in combination with chemotherapy with or without bevacizumab (Avastin, Genentech) among 1,202 patients with stage IV nonsquamous NSCLC.

Researchers randomly assigned patients 1:1:1 to atezolizumab plus carboplatin and paclitaxel, atezolizumab and bevacizumab plus carboplatin and paclitaxel, or bevacizumab plus carboplatin and paclitaxel.

Researchers excluded patients with ALK and EGFR mutations from the intention-to-treat analysis.

The study met its co-primary endpoint of OS with atezolizumab and bevacizumab plus chemotherapy, which appeared associated with increased survival compared with bevacizumab plus chemotherapy.

Atezolizumab plus chemotherapy did not appear to have a significant OS benefit compared with bevacizumab plus chemotherapy.

As HemOnc Today previously reported, atezolizumab and bevacizumab plus chemotherapy extended PFS by 38% among patients with NSCLC (HR = 0.62; 95% CI, 0.52-0.74) compared with bevacizumab plus chemotherapy.

The safety profile of the combination appeared consistent with the known safety profile of the individual agents.

“We are pleased that the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech, said in a company-issued press release. “These results add to the growing body of evidence supporting the role of combining Tecentriq with Avastin. We will submit these additional data to global health authorities and hope to bring this potential treatment option to patients as soon as possible.”